LRRK2 and Parkinson disease: Additionally, we observed that there were no significant differences in most of the clinical characteristics, including sex distribution, AAO, initial symptoms, motor symptoms and grade of severity, depression, and LED and levodopa-related complications between LRRK2 G2385R-carrier and LRRK2 G2385R-noncarrier PD patients.